Alcon Inc. (SWX:ALC)
Switzerland
· Delayed Price · Currency is CHF | Market Cap | 39.48B |
| Revenue (ttm) | 8.98B |
| Net Income (ttm) | 922.49M |
| Shares Out | 494.62M |
| EPS (ttm) | 1.86 |
| PE Ratio | 42.97 |
| Forward PE | 29.70 |
| Dividend | 0.28 (0.35%) |
| Ex-Dividend Date | May 13, 2025 |
| Volume | 1,044,554 |
| Average Volume | 923,195 |
| Open | 79.94 |
| Previous Close | 79.82 |
| Day's Range | 79.00 - 80.96 |
| 52-Week Range | 67.34 - 87.00 |
| Beta | 0.75 |
| RSI | 55.76 |
| Earnings Date | May 14, 2025 |
About Alcon
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. It operates through two segments, Surgical and Vision Care. The company offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, Verion reference unit and Verion digital marker, ... [Read more]
Financial Performance
In 2024, Alcon's revenue was $9.91 billion, an increase of 4.82% compared to the previous year's $9.46 billion. Earnings were $1.02 billion, an increase of 4.52%.
Financial numbers in USD Financial StatementsNews
Alcon Earnings Preview
Alcon (NYSE: ALC) is set to give its latest quarterly earnings report on Tuesday, 2025-05-13. Here's what investors need to know before the announcement. Analysts estimate that Alcon will report an e...
Alcon Announces Results of 2025 Annual General Meeting
GENEVA--(BUSINESS WIRE)--Alcon Announces Results of 2025 Annual General Meeting.
Alcon Elevates Vitreoretinal and Cataract Surgery for Superior Efficiency* with UNITY VCS and UNITY CS
GENEVA--(BUSINESS WIRE)--Alcon Elevates Vitreoretinal and Cataract Surgery for Superior Efficiency* with UNITY VCS and UNITY CS.
LENSAR: It Is All About The Contingent Value Right Now
LENSAR’s buyout by Alcon presents a strong headline value, but risks tied to the CVR and closing process persist. Find out why LNSR stock is a hold.
Alcon proposes CHF 0.28 dividend
Alcon: A Clear Vision, But Fully Valued
Alcon Inc (ALC) Announces Upcoming Annual General Meeting and Board Changes
Alcon Inc (ALC) Announces Upcoming Annual General Meeting and Board Changes
Alcon Publishes Agenda for 2025 Annual General Meeting
GENEVA--(BUSINESS WIRE)--Alcon Publishes Agenda for 2025 Annual General Meeting.
Alcon Publishes Agenda for 2025 Annual General Meeting
GENEVA--(BUSINESS WIRE)--Alcon Publishes Agenda for 2025 Annual General Meeting.
Alcon Expands Leadership in IOL Innovation with Clareon PanOptix Pro, Delivering Best-in-Class Light Utilization and Less Light Scatter
GENEVA--(BUSINESS WIRE)--Alcon Expands Leadership in IOL Innovation with Clareon PanOptix Pro, Delivering Best-in-Class Light Utilization and Less Light Scatter.
Alcon buys majority stake in Aurion Biotech
Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease
GENEVA--(BUSINESS WIRE)--Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease.
LENSAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LENSAR, Inc. - LNSR
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of LENSA...
Alcon Stock Sees RS Rating Climb To 74
A Relative Strength Rating upgrade for Alcon shows improving technical performance. Will it continue?
Alcon upgraded at BofA Securities to Buy on earnings growth potential
Alcon Inc (ALC) Launches Clareon Vivity IOL in Europe
Alcon Inc (ALC) Launches Clareon Vivity IOL in Europe
Alcon Announces CE Mark Approval and Commercialization of Clareon Vivity IOL in Europe, Expanding Visual Possibilities
GENEVA--(BUSINESS WIRE)--Alcon Announces CE Mark Approval and Commercialization of Clareon Vivity IOL in Europe, Expanding Visual Possibilities.
M&A Snapshot: Alcon to acquire LENSAR to boost its cataract equipment portfolio
Alcon Eyes Surgical Edge With LENSAR Buyout: Details
Alcon is set to acquire LENSAR Inc. in a ... Full story available on Benzinga.com
Alcon agrees to acquire LENSAR for $14.00 per share
Alcon Agrees to Acquire LENSAR, Inc.
GENEVA, Switzerland & ORLANDO, Fla.--(BUSINESS WIRE)--Alcon Agrees to Acquire LENSAR, Inc.
Retinal Surgery Devices Market Outlook Report 2025-2033: Revenues Set to Double, Reaching $4.83 Billion by 2033, Led by Topcon Corp., Alcon, and Carl Zeiss
Dublin, March 24, 2025 (GLOBE NEWSWIRE) -- The "Retinal Surgery Devices Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" has been added to ResearchAndMarkets.com's offerin...
Alcon to Host 2025 Capital Markets Day
GENEVA--(BUSINESS WIRE)--Alcon to Host 2025 Capital Markets Day.
Alcon to Host 2025 Capital Markets Day
GENEVA--(BUSINESS WIRE)--Alcon to Host 2025 Capital Markets Day.
Alcon Stock Gets Relative Strength Rating Lift
A Relative Strength Rating upgrade for Alcon shows improving technical performance. Will it continue?